AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportTempus AI vs Paige
Tempus AI
VS
Paige
Verdict by Category
Detailed Comparison
Feature
Tempus AI
Paige
Pricing
CustomTempus operates multiple revenue streams with different access models.
Clinical genomic tests (xT, xG, xR, xF, xE) are ordered by physicians through the standard laboratory test ordering process. Pricing varies by test type and is typically covered by insurance for oncology patients. Tempus works directly with health systems to integrate ordering into EHR workflows.
Enterprise data platform access, Algos population health analytics, and biopharma research partnerships are priced through custom enterprise licensing agreements. Biopharma companies license Tempus's de-identified patient datasets and analytical services for drug development and clinical trial design.
Tempus is publicly traded on NASDAQ (ticker: TEM) since June 2024. Investor and enterprise partnership inquiries can be directed through tempus.com.
EnterprisePaige operates exclusively on enterprise contracts with hospital pathology departments, cancer centers, and biopharma companies. There is no published pricing or self-serve option.
Clinical deployments are priced based on institution size, scanner ecosystem, patient volume, and AI modules deployed (FullFocus, Paige Prostate, Paige Breast, etc.). Biopharma partnerships are structured as research service agreements for biomarker discovery, companion diagnostic development, and drug trial tissue analysis.
Contact Paige through paige.ai to arrange an enterprise discovery call and platform demonstration.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
AI precision medicine platform — genomic profiling, clinical insights, and trial matching for personalized cancer care
Computational pathology AI from MSK — the first FDA-cleared platform for AI-assisted cancer diagnosis
Tempus AI Pros & Cons
Pros
- Publicly traded (NASDAQ: TEM) — one of the most credible precision medicine AI companies
- 7M+ de-identified patient records — one of the world's largest clinical-molecular datasets
- Comprehensive genomic testing across 6 test types covering all major oncology applications
- Tempus One AI provides real-time clinical insights at the point of care
- TIME Trial dramatically improves clinical trial matching and enrollment rates
- 3,800+ employees and $8.79B total capital raised since founding
- Expanding beyond oncology into neuropsychiatry, cardiology, and infectious disease
Cons
- Enterprise and institutional pricing — not accessible to individual clinicians or small practices
- Focused primarily on oncology and genomics — not a general-purpose clinical AI tool
- Genomic test turnaround requires laboratory processing time
- Data platform access and licensing requires formal agreements
- Some AI insights require institutional genomic data infrastructure to fully leverage
Paige Pros & Cons
Pros
- First FDA clearance for AI in primary pathology diagnosis — a historic regulatory milestone
- First CE mark for AI pathology in Europe — validated for clinical use across EU
- Founded on MSK's 25M+ pathology slides — the richest cancer pathology training set in the world
- AIRI infrastructure with 10+ petaFLOPS — enterprise-grade AI compute at clinical scale
- FullFocus viewer is scanner-neutral with FDA clearances for Leica, Hamamatsu, and Philips
- The most credentialed AI pathology company in terms of regulatory approvals
- Backed by Goldman Sachs, Breyer Capital, and Healthcare Venture Partners
Cons
- Enterprise and institutional access only — not available to small or independent pathology labs
- No published pricing — all contracts negotiated through enterprise procurement
- Requires digital pathology infrastructure — scanners, storage, and LIS integration
- Pathologist review and sign-off still required for all AI-generated results
- Focused on pathology and oncology — not a general medical imaging platform